Proven efficacy —
break down the clot with 2-mg Cathflo

In the COOL-1 clinical trial, Cathflo demonstrated 88% cumulative efficacy after up to 2 doses using a 2-hour dwell

Study design: COOL-1, a multicenter, double-blind, placebo-controlled comparison of the rates of restoration of catheter function after treatment for 2 hours with either alteplase 2 mg in 2 mL or placebo (N=150).

• COOL-2 — 85% cumulative efficacy after up to 2 doses using a 2-hour dwell
• CAPS—83% cumulative efficacy after up to 2 doses using a 2-hour dwell

In COOL-2, the largest published study of its kind, Cathflo demonstrated 75% first-dose efficacy after up to 120 minutes

Study design: COOL-2, an open-label, single-arm, multicenter trial in which 995 patients received treatment with up to 2 doses of Cathflo 2 mg using a 2-hour dwell.

Earlier intervention increases rate of restored catheter function1

In COOL-2, Cathflo demonstrated that shorter duration of occlusion correlates with a higher rate of restored catheter function1

Study design: COOL-2, an open-label, single-arm, multicenter trial in which 995 patients received treatment with up to 2 doses of Cathflo 2 mg using a 2-hour dwell.

• 91% functional restoration in CVADs obstructed less than 24 hours
• Restoration rates decreased with longer duration of occlusion

Reference:

• Deitcher SR, Fesen MR, Kiproff PM, et al, for the Cardiovascular Thrombolytic to Open Occluded Lines-2 Investigators. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the Cardiovascular Thrombolytic to Open Occluded Lines trial. J Clin Oncol. 2002;20:317-324.